#2075
Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
Introduction:
Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Antonijoan Arbós R,
Lachamp L,
Cabello F,
Molina P,
Coimbra J,
Keywords:
Apoc,
somatostatin,
analogues,
controlled release,
octreotide,
octreotide acetate,
phase 1,
studies,
clinical trial,
study,
neuroendocrine,
tumor,
slow,
release,
formulation,
therapeutics,
injection,
drug effect,
clinical,
trial,
im,
sc,
#815
The Effect of Autophagy Inhibitors Alone or in Combination with mTOR Inhibitors in a Neuroendocrine Tumor Cell Model
Introduction:
Most patients with neuroendocrine tumors (NETs) require systemic treatment, often with a limited therapeutic effect. RAD001 and Torin1 are mTOR inhibitors (mTORi) known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to escape the anti-proliferative effect and to prolong cell survival. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Glasberg S
Authors:
Avniel-Polak S,
Leibowitz G,
Glaser B,
Gross D,
Glasberg S,
Keywords:
NETs,
autophagy,
mTOR inhibitors,
